Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY: EW )

74.60 +4.14 (+5.87%)
Streaming Delayed Price Updated: 10:45 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Edwards Lifesciences

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Thursday's pre-market session: top gainers and losers in the S&P500 index
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales. 
Via Investor's Business Daily
Topics ETFs
A Look at Edwards Lifesciences's Upcoming Earnings Report
Via Benzinga
Is Edwards Lifesciences Gaining or Losing Market Support?
Via Benzinga
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
A Look Into Edwards Lifesciences Inc's Price Over Earnings
Via Benzinga
Peering Into Edwards Lifesciences's Recent Short Interest
Via Benzinga
11 Analysts Have This To Say About Edwards Lifesciences
Via Benzinga
Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence. 
Via Benzinga
Topics Government
Exposures Political
Earnings Scheduled For April 23, 2025
Via Benzinga
Assessing Edwards Lifesciences: Insights From 20 Financial Analysts
Via Benzinga
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock
Via Benzinga
How Is The Market Feeling About Edwards Lifesciences?
Via Benzinga
Top S&P500 movers in Wednesday's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025. 
Via Benzinga
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Discover the top S&P500 movers in Wednesday's pre-market session.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
Edwards Beats Fourth-Quarter Forecasts, But Shares Slip
Edwards Lifesciences stock fell slightly late Tuesday after the company kept its outlook for 2025 despite beating forecasts. 
Via Investor's Business Daily
Edwards Lifesciences (EW) Reports Q4: Everything You Need To Know Ahead Of Earnings
Medical technology company Edwards Lifesciences (NYSE:EW) will be reporting results tomorrow after market close. Here’s what to look for. 
Via StockStory
Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business changes for 2025. 
Via Benzinga
This Coca-Cola Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
U.S. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Jan. 18
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Jan. 13-17, 2025. 
Via Talk Markets
Topics Stocks / Equities
Earnings Scheduled For February 11, 2025
Via Benzinga
Good technical signals and a possible breakout for EDWARDS LIFESCIENCES CORP.
EDWARDS LIFESCIENCES CORP (NYSE:EW) has a strong technical rating of 7 out of 10, indicating a potential breakout. 
Via Chartmill
Technical Signals Point to a Possible Breakout for EDWARDS LIFESCIENCES CORP.
With a solid technical rating of 7 out of 10, EDWARDS LIFESCIENCES CORP (NYSE:EW) is showing strong indications of a possible breakout. 
Via Chartmill
Edwards Lifesciences Outlines Vision For Growth At Investor Conference
Edwards Lifesciences outlines 2025 growth strategy, emphasizing innovations in TAVR and TMTT therapies, with a projected sales growth of 8%-10% and expanded patient care. 
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.